Differences between graft product and donor side effects following bone marrow or stem cell donation

Creative Commons License

Favre G., BEKSAÇ M., Bacigalupo A., Ruutu T., Nagler A., Gluckman E., ...More

BONE MARROW TRANSPLANTATION, vol.32, no.9, pp.873-880, 2003 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 32 Issue: 9
  • Publication Date: 2003
  • Doi Number: 10.1038/sj.bmt.1704245
  • Journal Name: BONE MARROW TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.873-880
  • Keywords: allogeneic hematopoietic stem cell transplantation, peripheral blood stem cells, granulocyte colony-stimulating factor, leukapheresis, donor safety, PERIPHERAL-BLOOD STEM, COLONY-STIMULATING FACTOR, PROGENITOR-CELL, ALLOGENEIC TRANSPLANTATION, RANDOMIZED-TRIAL, EUROPEAN-GROUP, MOBILIZATION, LEUKEMIA, EXPERIENCE, FILGRASTIM
  • Open Archive Collection: AVESIS Open Access Collection
  • Ankara University Affiliated: Yes

Abstract

We report graft product stem cell yields and donor safety results of a randomized multicenter study comparing allogeneic peripheral blood stem cell (PBSC) PBSC transplantation with BM trans plantation. Matched HLA-identical sibling donors (n = 329) were randomized to filgrastim-mobilized PBSC or bone marrow (BM) donation groups. Median yields per kg recipient weight of CD34(+) cells, T cells, and natural killer (NK) cells, respectively, were approximately two-fold, eight-fold, and greater than eight-fold in the PBSC group than in the BM group (CD34(+) cells, 5.8 x 10(6)/kg vs 2.7 x 10(6)/kg; T cells, 300.1 x 10(6)/kg vs 35.7 x 10(6)/kg; NK cells, 28.2 x 10(6)/kg vs 3.6 x 10(6)/kg; P < 0.001 for each). In connection with the cell collection procedures, PBSC donors spent a shorter median time in hospital than BM donors (0 vs 2 days; median difference -2 days, 95% CI -2 to 2) and had fewer median days of restricted activity (2 vs 6 days; median difference -3 days, 95% CI -4 to 2). Overall, 65% of PBSC donors and 57% of BM donors reported at least one adverse event (AE), most of which were transient, mild-moderate in severity, and without clinical sequelae. PBSC donors experienced predominantly filgrastim-related AEs, while BM donors experienced predominantly harvest-related AEs.